ALX Oncology Holdings Inc.

ALXO Healthcare Biotechnology

In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.06 0.06 +6.00%
Market cap
$138.3M
P/E
0.0×
Fwd P/E
−8.6×
Dividend yield
—
F-score
n/a
Altman Z
154.45
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.40 2.07 7.21 9.71
Net Debt/EBITDA
2.24 1.52 6.96 7.05
Debt/Equity
0.23 0.38 0.06 0.07
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.32) (0.35) (0.18) (0.12)
Book value per Share
0.84 0.48 1.45 1.00
Free Cash Flow
(17.15) (19.03) (18.70) (16.03)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates